Neuraxis Inc. Common Stock (NRXS)
Stock · AMEX · Health Care
$7.7as of 10/16/2026
Price chart
Active signals
NRXS Signal Track Record
How signals performed across all stocks →What NRXS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 21 | +0.4% | 52% | September 14, 2026 |
| Bollinger Band Breakout | 14 | -4.1% | 43% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +4.6% | 64% | September 2, 2026 |
| Bollinger Band Breakdown | 9 | +17.9% | 67% | July 28, 2026 |
| Any 20-session window (baseline) | +0.8% | 52% |
Computed by MarketWall from daily closing prices since May 23, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NRXS
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and as…
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Employees
- 24
- Website
- neuraxis.com/
Fundamentals
- 1-day range
- $6.8$7.81
- Market cap
- $86.47M
- P/E (trailing)
- —
- P/E (forward)
- -28.67
- EPS (trailing)
- $-0.71
- Dividend yield
- —
- Beta
- 1.41
- Avg. volume
- 124.5K
How Neuraxis Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Neuraxis Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NRXSNeuraxis Inc. Common Stock$7.7▼ 0.52%Market cap $86.47MP/E —$2.21$9.33
- OMOutset Medical Inc. Common Stock$3.94▼ 3.43%Market cap $96.39MP/E —$2.84$15.94
- HYPRHyperfine Inc. Class A Common Stock$0.755▼ 3.21%Market cap $97.48MP/E —$0.7536$2.22
- STEXStreamex Corp. Common Stock$0.374▼ 8.33%Market cap $75.35MP/E —$0.3876$6.5
- HSDTSolana Company Class A Common Stock (DE)$2.24▼ 4.68%Market cap $98.09MP/E —$1.19$16.81
- ECORelectroCore Inc. Common Stock$7.85▼ 5.99%Market cap $60.41MP/E —$4.41$12.7
- VANIVivani Medical Inc. Common Stock (DE)$1.12▼ 2.61%Market cap $117.28MP/E —$0.9227$1.92
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NRXS Neuraxis Inc. Common Stock | $86.47M | — | $7.7 | ▼ 0.52% | $2.21$9.33 |
| OM Outset Medical Inc. Common Stock | $96.39M | — | $3.94 | ▼ 3.43% | $2.84$15.94 |
| HYPR Hyperfine Inc. Class A Common Stock | $97.48M | — | $0.755 | ▼ 3.21% | $0.7536$2.22 |
| STEX Streamex Corp. Common Stock | $75.35M | — | $0.374 | ▼ 8.33% | $0.3876$6.5 |
| HSDT Solana Company Class A Common Stock (DE) | $98.09M | — | $2.24 | ▼ 4.68% | $1.19$16.81 |
| ECOR electroCore Inc. Common Stock | $60.41M | — | $7.85 | ▼ 5.99% | $4.41$12.7 |
| VANI Vivani Medical Inc. Common Stock (DE) | $117.28M | — | $1.12 | ▼ 2.61% | $0.9227$1.92 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- NeurAxis Announces Its Medical Policy Coverage Now Serves Over 26M Medical Plan Membersbenzinga · 10/15/2026
- NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial OfficerYahoo · 9/29/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 9/16/2026
- NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered LivesYahoo · 9/16/2026
- NeurAxis to Participate in the Lytham Partners Fall 2026 Investor ConferenceYahoo · 9/16/2026
- Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?Yahoo · 9/15/2026
- iAccess Alpha Virtual Best Ideas Fall Investment Conference Begins Today with Updated Presentation ScheduleYahoo · 9/15/2026
- NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 TranscriptSeekingAlpha · 9/15/2026
- Is Kodak having a "Kodak moment?" 2 watchlist stocks.Yahoo · 9/12/2026
Insider Activity
Insider Actions →- Brian Allen Carrico · October 8, 2026 · Buy268 @ $4.84
- Thomas Joeseph Carrico · October 8, 2026 · Buy328 @ $4.84
- Timothy Robert Henrichs · October 8, 2026 · Buy1.9K @ $4.84
- Miranda Adrian · August 24, 2026 · Conversion337.2K @ $6.94
- Miranda Adrian · August 24, 2026 · Grant337.2K
- Miranda Adrian · August 24, 2026 · Grant199.1K
- Thomas Joeseph Carrico · August 24, 2026 · Conversion306.2K @ $6.94
- Thomas Joeseph Carrico · August 24, 2026 · Grant306.2K
- Thomas Joeseph Carrico · August 24, 2026 · Grant193.7K
- Brian Allen Carrico · August 24, 2026 · Conversion320.0K @ $6.94
- Brian Allen Carrico · August 24, 2026 · Grant320.0K
- Brian Allen Carrico · August 24, 2026 · Grant199.2K
- Bradley Mitchell Watkins · August 13, 2026 · Grant26.1K @ $6.28
- Miranda Adrian · August 13, 2026 · Grant133.3K @ $6.28
- Jane Elizabeth Keyser · August 13, 2026 · Grant26.1K @ $6.28
Institutional Ownership
March 31, 2026
- Total shares held
- 1.99M
- Total value held
- $14.21M
- Institutional holders
- 25
- Unknown400.0K
- Unknown286.1K
- Unknown225.9K
- Unknown225.6K
- Unknown190.0K
- Unknown116.7K
- Unknown93.1K
- Unknown78.7K
- Unknown77.0K
- Unknown50.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
NeurAxis Names Craig Blanchard CCO to Drive Commercial Growth
NeurAxis has appointed Craig Blanchard as chief commercial officer to lead the next phase of commercial growth. The move signals the company’s focus on expanding market reach and accelerating product commercialization. Blanchard’s experience is expected to help the firm move from development to broader market adoption.
NeurAxis Names Craig Blanchard CCO to Drive Commercial Growth. NeurAxis has appointed Craig Blanchard as chief commercial officer to lead the next phase of commercial growth. The move signals the company’s focus on expanding market reach and accelerating product commercialization. Blanchard’s experience is expected to help the firm move from development to broader market adoption.